Ropeginterferon Alfa-2b Controls Polycythemia Vera and Cuts Phlebotomy Needs in Practice
A real-world study finds ropeginterferon alfa-2b achieved progressive hematologic control and substantially lowered phlebotomy requirements in patients with polycythemia vera.

